At Mölnlycke we fully support the NHS’s drive towards an approach which maximises savings opportunities across the patient pathway, and improve patient outcomes, however we appreciate that this move is currently slowed/hindered by the COVID-19 pandemic and, rightly so, focus is being paid to ensuring essential services are maintained during this time.
In response to the immediate challenge for the NHS to make cost savings, we have taken the step to reduce the price of our Mepilex® Border dressings, allowing clinicians to access a trusted and valued product for their patients at a price point which resonates with budget decision makers.
We wish to reassure our customers that we haven’t made any changes in the way we are manufacturing Mepilex Border dressings, these are manufactured to the same high quality as they always have been and that is synonymous with Mölnlycke products.
Whilst we are offering this saving, we remain focussed on delivering a market leading added value service, to support you both clinically and strategically across your whole patient pathway.
